Azathioprine for multiple sclerosis

I. Casetta, G. Iuliano, G. Filippini

Research output: Contribution to journalArticle

Abstract

Background: Azathioprine (AZA) is an immunosuppressive drug widely prescribed for the treatment of multiple sclerosis (MS) until the first half of the 1990s. It could be an alternative to interferon β because it is less expensive. Concerns about its safety, mainly a possible increased risk of malignancy, have been raised. This systematic review aimed to determine the trade off between the benefits and risks of azathioprine in MS. Objectives: To compare azathioprine with placebo. To assess the effect of azathioprine on major clinical outcomes (ie, disability progression and relapses) in patients with MS, and to evaluate the drug's safety. Methods: The Cochrane MS Group search strategy was adopted to identify relevant articles. All randomised controlled trials comparing azathioprine treatment of a least 1 year duration with placebo for patients with MS were eligible for the review. Cohorts, case controls, case series and case reports were also considered to assess adverse effects. Regulatory agencies were additional sources of information for adverse effects. More details are available in the full review.

Original languageEnglish
Pages (from-to)131-132
Number of pages2
JournalJournal of Neurology, Neurosurgery and Psychiatry
Volume80
Issue number2
DOIs
Publication statusPublished - Feb 2009

Fingerprint

Azathioprine
Multiple Sclerosis
Placebos
Safety
Immunosuppressive Agents
Pharmaceutical Preparations
Interferons
Randomized Controlled Trials
Recurrence
Therapeutics
Neoplasms

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Surgery
  • Medicine(all)

Cite this

Azathioprine for multiple sclerosis. / Casetta, I.; Iuliano, G.; Filippini, G.

In: Journal of Neurology, Neurosurgery and Psychiatry, Vol. 80, No. 2, 02.2009, p. 131-132.

Research output: Contribution to journalArticle

Casetta, I. ; Iuliano, G. ; Filippini, G. / Azathioprine for multiple sclerosis. In: Journal of Neurology, Neurosurgery and Psychiatry. 2009 ; Vol. 80, No. 2. pp. 131-132.
@article{e8c7831a9165494c9120ab5ead8f3e05,
title = "Azathioprine for multiple sclerosis",
abstract = "Background: Azathioprine (AZA) is an immunosuppressive drug widely prescribed for the treatment of multiple sclerosis (MS) until the first half of the 1990s. It could be an alternative to interferon β because it is less expensive. Concerns about its safety, mainly a possible increased risk of malignancy, have been raised. This systematic review aimed to determine the trade off between the benefits and risks of azathioprine in MS. Objectives: To compare azathioprine with placebo. To assess the effect of azathioprine on major clinical outcomes (ie, disability progression and relapses) in patients with MS, and to evaluate the drug's safety. Methods: The Cochrane MS Group search strategy was adopted to identify relevant articles. All randomised controlled trials comparing azathioprine treatment of a least 1 year duration with placebo for patients with MS were eligible for the review. Cohorts, case controls, case series and case reports were also considered to assess adverse effects. Regulatory agencies were additional sources of information for adverse effects. More details are available in the full review.",
author = "I. Casetta and G. Iuliano and G. Filippini",
year = "2009",
month = "2",
doi = "10.1136/jnnp.2008.144972",
language = "English",
volume = "80",
pages = "131--132",
journal = "Journal of Neurology, Neurosurgery and Psychiatry",
issn = "0022-3050",
publisher = "BMJ Publishing Group",
number = "2",

}

TY - JOUR

T1 - Azathioprine for multiple sclerosis

AU - Casetta, I.

AU - Iuliano, G.

AU - Filippini, G.

PY - 2009/2

Y1 - 2009/2

N2 - Background: Azathioprine (AZA) is an immunosuppressive drug widely prescribed for the treatment of multiple sclerosis (MS) until the first half of the 1990s. It could be an alternative to interferon β because it is less expensive. Concerns about its safety, mainly a possible increased risk of malignancy, have been raised. This systematic review aimed to determine the trade off between the benefits and risks of azathioprine in MS. Objectives: To compare azathioprine with placebo. To assess the effect of azathioprine on major clinical outcomes (ie, disability progression and relapses) in patients with MS, and to evaluate the drug's safety. Methods: The Cochrane MS Group search strategy was adopted to identify relevant articles. All randomised controlled trials comparing azathioprine treatment of a least 1 year duration with placebo for patients with MS were eligible for the review. Cohorts, case controls, case series and case reports were also considered to assess adverse effects. Regulatory agencies were additional sources of information for adverse effects. More details are available in the full review.

AB - Background: Azathioprine (AZA) is an immunosuppressive drug widely prescribed for the treatment of multiple sclerosis (MS) until the first half of the 1990s. It could be an alternative to interferon β because it is less expensive. Concerns about its safety, mainly a possible increased risk of malignancy, have been raised. This systematic review aimed to determine the trade off between the benefits and risks of azathioprine in MS. Objectives: To compare azathioprine with placebo. To assess the effect of azathioprine on major clinical outcomes (ie, disability progression and relapses) in patients with MS, and to evaluate the drug's safety. Methods: The Cochrane MS Group search strategy was adopted to identify relevant articles. All randomised controlled trials comparing azathioprine treatment of a least 1 year duration with placebo for patients with MS were eligible for the review. Cohorts, case controls, case series and case reports were also considered to assess adverse effects. Regulatory agencies were additional sources of information for adverse effects. More details are available in the full review.

UR - http://www.scopus.com/inward/record.url?scp=60249099406&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=60249099406&partnerID=8YFLogxK

U2 - 10.1136/jnnp.2008.144972

DO - 10.1136/jnnp.2008.144972

M3 - Article

C2 - 19151017

AN - SCOPUS:60249099406

VL - 80

SP - 131

EP - 132

JO - Journal of Neurology, Neurosurgery and Psychiatry

JF - Journal of Neurology, Neurosurgery and Psychiatry

SN - 0022-3050

IS - 2

ER -